Synopsis
Synopsis
0
EU WC
0
VMF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Carteolol
2. Carteolol Monohydrochloride
3. Hydrochloride, Carteolol
4. Monohydrochloride, Carteolol
5. Opc 1085
6. Opc-1085
7. Opc1085
1. 51781-21-6
2. Carteolol Hcl
3. Arteoptic
4. Cartrol
5. Mikelan
6. Abbott-43326
7. Ocupress
8. Endak Hydrochloride
9. Opc-1085
10. Opc-1085 Hydrochloride
11. Carteolol (hydrochloride)
12. Nsc-300906
13. Endak
14. 5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydrocarbostyril Monohydrochloride
15. 4797w6i0t4
16. Carbonolol
17. Endak Mite
18. Abbott 43326
19. 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-2(1h)-quinolinone Hydrochloride
20. Dsstox_cid_25478
21. Dsstox_rid_80904
22. Dsstox_gsid_45478
23. 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, Monohydrochloride
24. 5-(2-hydroxy-3-tert-butylamino)propoxy-3,4-dihydrocarbostyril Hydrochloride
25. Teoptic
26. Chebi:3438
27. 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinolin-2-one Hydrochloride
28. 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-2(1h)-quinolinone Hydrochloride
29. 5-(3-tert-butylamino-2-hydroxy-propoxy)-3,4-dihydro-2(1h)-chinolinon-hydrochlorid
30. Opc 1085
31. Einecs 257-415-7
32. Dl-carteolol Hydrochloride
33. Nsc 300906
34. Arteolol
35. Carteol
36. Unii-4797w6i0t4
37. Mikelan La
38. 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydrocarbostyril Monohydrochloride
39. Ocupress (tn)
40. Cartrol (tn)
41. Carteolol Hydrochloride [usan:usp:jan]
42. 5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydroquinolin-2(1h)-one Hydrochloride
43. Ncgc00016865-01
44. 5-(3-tert-butylamino-2-hydroxy)propoxy-3,4-dihydrocarbostyril Hydrochloride
45. Cas-51781-21-6
46. 5-(3-tert-butylamino-2-hydroxy-propoxy)-3,4-dihydro-2(1h)-chinolinon-hydrochlorid [german]
47. Schembl41380
48. Mls002153816
49. Carteolol Hydrochloride ,(s)
50. Chembl1201002
51. Dtxsid4045478
52. Hms1569i14
53. Pharmakon1600-01505519
54. Bcp28338
55. Ex-a1257
56. Carteolol Hydrochloride [mi]
57. Tox21_110654
58. Carteolol Hydrochloride (jp17/usp)
59. Carteolol Hydrochloride [jan]
60. Hy-17495a
61. Mfcd00941499
62. Nsc300906
63. Nsc760060
64. S4278
65. Carteolol Hydrochloride [usan]
66. Akos027379166
67. Tox21_110654_1
68. Carteolol Hydrochloride [mart.]
69. Carteolol Hydrochloride [vandf]
70. Ccg-213475
71. Nsc-760060
72. 5-(3-((tert-butyl)amino)-2-hydroxypropoxy)-3,4-dihydro-2-quinolone Monohydrochloride
73. 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1h-quinolin-2-one;hydrochloride
74. Carteolol Hydrochloride [usp-rs]
75. Carteolol Hydrochloride [who-dd]
76. Ncgc00179541-03
77. As-74897
78. Smr001233186
79. Db-052022
80. B5944
81. Carteolol Hydrochloride [orange Book]
82. Ft-0640026
83. Sw197155-3
84. Carteolol Hydrochloride [usp Impurity]
85. C75429
86. Carteolol Hydrochloride [usp Monograph]
87. D00599
88. Wln: T66 Bmvt&j Go1yq1mx1&1&1 &gh
89. Sr-01000841202
90. Sr-01000841202-2
91. Q27106078
92. 5-(3-t-butylamino-2-hydroxypropoxy)-3,4-dihydrocarbostyril Hydrochloride
93. 2(1h)-quinolinone,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, Monohydrochloride
94. 2(1h)-quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro, Monohydrochloride
95. 2(1h)-quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2hydroxypropoxy]-3,4-dihydro, Monohydrochloride
Molecular Weight | 328.83 g/mol |
---|---|
Molecular Formula | C16H25ClN2O3 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 6 |
Exact Mass | 328.1553704 g/mol |
Monoisotopic Mass | 328.1553704 g/mol |
Topological Polar Surface Area | 70.6 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 354 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Carteolol hydrochloride |
Drug Label | Carteolol Hydrochloride Ophthalmic Solution USP, 1% is a nonselective beta-adrenoceptor blocking agent for ophthalmic use.The chemical name for carteolol hydrochloride is ()-5-[3-[(1,1-dimethylethyl) amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quino... |
Active Ingredient | Carteolol hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 1% |
Market Status | Prescription |
Company | Alcon; Bausch And Lomb |
2 of 4 | |
---|---|
Drug Name | Ocupress |
PubMed Health | Carteolol |
Drug Classes | Antiglaucoma, Antihypertensive, Cardiovascular Agent |
Drug Label | Ocupress (carteolol hydrochloride ophthalmic solution), 1%, is a nonselective beta-adrenoceptor blocking agent for ophthalmic use.The chemical name for carteolol hydrochloride is ()5[3[(1,1dimethylethyl) amino]2 hydroxypropoxy]3... |
Active Ingredient | Carteolol hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 1% |
Market Status | Prescription |
Company | Novartis |
3 of 4 | |
---|---|
Drug Name | Carteolol hydrochloride |
Drug Label | Carteolol Hydrochloride Ophthalmic Solution USP, 1% is a nonselective beta-adrenoceptor blocking agent for ophthalmic use.The chemical name for carteolol hydrochloride is ()-5-[3-[(1,1-dimethylethyl) amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quino... |
Active Ingredient | Carteolol hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 1% |
Market Status | Prescription |
Company | Alcon; Bausch And Lomb |
4 of 4 | |
---|---|
Drug Name | Ocupress |
PubMed Health | Carteolol |
Drug Classes | Antiglaucoma, Antihypertensive, Cardiovascular Agent |
Drug Label | Ocupress (carteolol hydrochloride ophthalmic solution), 1%, is a nonselective beta-adrenoceptor blocking agent for ophthalmic use.The chemical name for carteolol hydrochloride is ()5[3[(1,1dimethylethyl) amino]2 hydroxypropoxy]3... |
Active Ingredient | Carteolol hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | 1% |
Market Status | Prescription |
Company | Novartis |
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
Carteolol for system suitability
Carteolol for system suitability
CAS Number : 51781-21-6
Quantity Per Vial : 30 mg
Sale Unit : 1
Order Code : Y0000193
Batch No : 1
Price (€) : 79
Storage : +5°C ± 3°C
Carteolol hydrochloride - reference spec...
Carteolol hydrochloride - reference spectrum
CAS Number : n/a
Quantity Per Vial : n/a
Sale Unit : 1
Order Code : Y0000192
Batch No : 1
Price (€) : 79
Storage :
Dehydrocarteolol Hydrochloride (100 mg)
CAS Number : N/A
Quantity Per Vial :
Price ($) : 730
Catalog Number : 1166400
Current Lot : F
Previous Lot :
NDC Code :
Carteolol Hydrochloride (200 mg)
CAS Number : 51781-21-6
Quantity Per Vial :
Price ($) : 230
Catalog Number : 1096757
Current Lot : G0F326
Previous Lot : F-1 (31-DEC-2007)
NDC Code :
ABOUT THIS PAGE
A Carteolol Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carteolol Hydrochloride, including repackagers and relabelers. The FDA regulates Carteolol Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carteolol Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carteolol Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carteolol Hydrochloride supplier is an individual or a company that provides Carteolol Hydrochloride active pharmaceutical ingredient (API) or Carteolol Hydrochloride finished formulations upon request. The Carteolol Hydrochloride suppliers may include Carteolol Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Carteolol Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carteolol Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Carteolol Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Carteolol Hydrochloride DMFs exist exist since differing nations have different regulations, such as Carteolol Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carteolol Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Carteolol Hydrochloride USDMF includes data on Carteolol Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carteolol Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carteolol Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Carteolol Hydrochloride Drug Master File in Japan (Carteolol Hydrochloride JDMF) empowers Carteolol Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Carteolol Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Carteolol Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Carteolol Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carteolol Hydrochloride Drug Master File in Korea (Carteolol Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carteolol Hydrochloride. The MFDS reviews the Carteolol Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Carteolol Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carteolol Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carteolol Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carteolol Hydrochloride suppliers with KDMF on PharmaCompass.
A Carteolol Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Carteolol Hydrochloride Certificate of Suitability (COS). The purpose of a Carteolol Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carteolol Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carteolol Hydrochloride to their clients by showing that a Carteolol Hydrochloride CEP has been issued for it. The manufacturer submits a Carteolol Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carteolol Hydrochloride CEP holder for the record. Additionally, the data presented in the Carteolol Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carteolol Hydrochloride DMF.
A Carteolol Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carteolol Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Carteolol Hydrochloride suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carteolol Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carteolol Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carteolol Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carteolol Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carteolol Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carteolol Hydrochloride suppliers with NDC on PharmaCompass.
Carteolol Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carteolol Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carteolol Hydrochloride GMP manufacturer or Carteolol Hydrochloride GMP API supplier for your needs.
A Carteolol Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Carteolol Hydrochloride's compliance with Carteolol Hydrochloride specifications and serves as a tool for batch-level quality control.
Carteolol Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Carteolol Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carteolol Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Carteolol Hydrochloride EP), Carteolol Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carteolol Hydrochloride USP).
LOOKING FOR A SUPPLIER?